-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Today, Arkuda Therapeutics announced the completion of a $64 million Series B financing
Arkuda is working to develop a small molecule therapy that modulates progranulin, which plays an important role in lysosomal function and innate immunity in the brain
Image source: Arkuda's official website
The company also plans to explore the efficacy of these compounds in a variety of neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease
References:
[1] Lilly, Pfizer-backed Arkuda bags $64M to test drug in frontotemporal dementia in 2023.
[2] ARKUDA THERAPEUTICS RAISES $64 MILLION SERIES B FINANCING TO ADVANCE PIPELINE OF PROGRAMS TARGETING LYSOSOMAL BIOLOGY TO TREAT NEURODEGENERATIVE DISEASES.
(Original abridged)